Highlights

  • Starpharma develops dendrimer-based drug delivery technology for pharmaceutical applications.
  • The DEP platform encompasses clinical-stage chemotherapy formulations and radiopharmaceutical research.
  • In July 2026, the company outlined a fully underwritten entitlement offer of approximately $32 million.
  • The proposed funding included first-in-human and dose-escalation work for DEP HER2-Lu.
  • Clinical validation, research expenditure and regulatory requirements remain central to development.

Starpharma Holdings Limited (ASX:SPL) is an Australian biotechnology company developing dendrimer-based drug delivery technologies, including its proprietary DEP platform. Its 2026 activities have included work on targeted oncology candidates, radiopharmaceuticals and funding arrangements intended to support further research and clinical development.

How DEP Technology Is Used in Oncology

The DEP platform uses highly branched, nanoscale dendrimer molecules as carriers for pharmaceutical agents. These structures can be engineered to alter drug solubility, delivery and distribution. Starpharma (ASX:SPL) is applying the technology across chemotherapy formulations and emerging targeted radiopharmaceutical programs. The mechanisms under investigation are distinct from established clinical benefits: performance must be assessed separately for each candidate and indication.

The company identifies DEP SN38, DEP cabazitaxel and DEP docetaxel among its clinical-stage oncology assets. Its corporate pipeline describes these as dendrimer formulations of existing anticancer drugs. Starpharma (ASX:SPL) has reported clinical studies of these candidates, but they should not be confused with medicines carrying marketing authorisation. The company’s published pipeline states that the three clinical-stage formulations have not received marketing or regulatory authorisation in any jurisdiction.

HER2-Targeted Radiopharmaceutical Development in 2026

A separate development area is targeted radiopharmaceuticals, which combine molecular targeting with radioactive material for diagnostic imaging or treatment. In July 2026, Starpharma presented preclinical data and its proposed first-in-human pathway for DEP HER2-Lutetium, known as DEP HER2-Lu. This candidate is being developed around the HER2 target associated with certain cancers. Preclinical findings do not establish safety or efficacy in patients.

Starpharma (ASX:SPL) has also described a HER2-targeted radiodiagnostic candidate in its pipeline. Imaging and treatment applications require different evidence and regulatory assessments. Development milestones therefore include formulation work, manufacturing controls, studies of radiation exposure and clinical assessment where authorised. The distinction matters when interpreting scientific progress across the broader DEP platform.

Capital Raising and Clinical Funding Priorities

On 15 July 2026, Starpharma announced an intention to raise approximately $32 million through a fully underwritten, renounceable pro-rata entitlement offer. Its shareholder communication dated 23 July 2026 specified an entitlement of one new share for every 7.5 existing shares at $0.57 per new share. These terms relate to the announced offer, rather than to a current market quotation.

According to the company, the proposed use of net proceeds included completing the first-in-human and dose-escalation stages of the DEP HER2-Lu Phase 1 study and advancing other targeted dendrimer oncology assets. For Starpharma (ASX:SPL), these purposes reflect the cash requirements of clinical research, but the existence of a fundraising plan alone does not verify a particular future cash runway or clinical result.

Development and Commercialisation Considerations

The progression of investigational drugs depends on clinical evidence, participant safety monitoring, manufacturing consistency and regulator decisions. Potential changes in trial protocols, recruitment rates or research expenditure can influence the timing of Starpharma’s work. Technology licensing arrangements and commercial partnerships also depend on counterparties reaching agreed development objectives.

For Starpharma (ASX:SPL), results from one DEP candidate cannot automatically be transferred to another. Different active ingredients, target tissues and delivery applications can produce different risk profiles. Clinical and preclinical evidence therefore needs to be interpreted in the context of each individual program.

Key Insights

Starpharma’s 2026 disclosures place DEP HER2-Lu and broader targeted oncology research within the company’s development priorities. The announced entitlement offer was designed to provide additional funding for that work. Preclinical research, human assessment and regulatory authorisation each require distinct evidence.